HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane.
Breast Cancer Res Treat
; 196(3): 571-581, 2022 Dec.
Article
in En
| MEDLINE
| ID: mdl-36280642
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Breast Neoplasms
/
Antineoplastic Agents
Type of study:
Clinical_trials
/
Etiology_studies
Aspects:
Patient_preference
Limits:
Female
/
Humans
Language:
En
Journal:
Breast Cancer Res Treat
Year:
2022
Document type:
Article
Affiliation country: